Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiora Pharmaceuticals (KPRX) Liabilities and Shareholders Equity (2016 - 2025)

Kiora Pharmaceuticals (KPRX) has disclosed Liabilities and Shareholders Equity for 11 consecutive years, with $29.9 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Liabilities and Shareholders Equity fell 22.45% year-over-year to $29.9 million, compared with a TTM value of $98.3 million through Sep 2025, down 27.45%, and an annual FY2024 reading of $36.5 million, up 166.08% over the prior year.
  • Liabilities and Shareholders Equity was $29.9 million for Q3 2025 at Kiora Pharmaceuticals, down from $31.9 million in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $42.4 million in Q1 2024 and bottomed at $146605.0 in Q3 2021.
  • Average Liabilities and Shareholders Equity over 5 years is $23.3 million, with a median of $19.9 million recorded in 2023.
  • The sharpest move saw Liabilities and Shareholders Equity plummeted 98.41% in 2021, then skyrocketed 11947.55% in 2022.
  • Year by year, Liabilities and Shareholders Equity stood at $20.1 million in 2021, then decreased by 12.26% to $17.7 million in 2022, then decreased by 22.37% to $13.7 million in 2023, then surged by 166.08% to $36.5 million in 2024, then decreased by 18.15% to $29.9 million in 2025.
  • Business Quant data shows Liabilities and Shareholders Equity for KPRX at $29.9 million in Q3 2025, $31.9 million in Q2 2025, and $36.5 million in Q4 2024.